Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs Nike Inc (NKE) Price & Performance

Ionis Pharmaceuticals Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Ionis Pharmaceuticals Inc. Common Stock vs Nike Inc — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B), while Nike Inc trades at $35.27 (market cap $52.48B). The key difference: Nike Inc is far larger — about 7.5× Ionis Pharmaceuticals Inc. Common Stock's market cap, and Nike Inc pays a 4.64% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Nike Inc for 155 Days on average.

IONSNKE
Market Cap
$7.04B$52.48B
Volume
2,977,44030,189,626
Sector
HealthConsumer Cyclical
52-Week High
$86.50$69.68
52-Week Low
$42.38$33.87
Typical Hold Time
0 Days155 Days
Enterprise Value
$6.60B$55.18B
Dividend Yield
—4.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ionis Pharmaceuticals Inc. Common Stock

No Aura AI signal available yet.

Nike Inc

Nike (NKE) trades at $35.35, up 1.84% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from declining revenue ($46.31B in 2025 vs. $51.4B in 2024) and compressed margins (net margin 6.74%), though valuation appears reasonable with P/E of 16.9. Analyst consensus remains mixed with 47% buy ratings but a $36.80 price target suggesting limited upside. Recent news highlights inventory challenges and China market pressures.

Nike's turnaround strategy focuses on inventory discipline and digital DTC growth, but execution risks persist amid weak consumer demand. The stock offers moderate value at current levels with dividend support, though revenue stabilization is critical for sustained recovery. Near-term catalysts include Q4 2026 earnings on June 30, 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IONS
100% Buy0% Sell
Avg holding period · 0 Days
NKE
4% Buy96% Sell
Avg holding period · 155 Days

About Ionis Pharmaceuticals Inc. Common Stock

Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.

Read more on IONS →

About Nike Inc

NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.

Read more on NKE →